RxDoctor Payments DataLook up a doctor →

Paul Davis, MD

Family Medicine · Wichita, KSNPI 1710980164

Payments from drug & device makers

$18,287in general payments, 2019–2025

Across 1,425 payments — averaging $12.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$2K
  • Amgen$1K
  • AbbVie$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • plus $9K from 51 others

What the payments were for

  • Food & beverage$18,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,287 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$207,042
Medicare patients
556
Services billed
5,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$69,523
EliquisApixaban51$52,687
JardianceEmpagliflozin36$40,878
TrulicityDulaglutide29$29,950
MounjaroTirzepatide27$29,370
FarxigaDapagliflozin Propanediol25$28,463
RybelsusSemaglutide13$24,185
XareltoRivaroxaban20$16,732
Repatha SureclickEvolocumab17$16,018
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,394
Soliqua 100-33Insulin Glargine/Lixisenatide16$14,322
MyrbetriqMirabegron14$12,857
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$6,917
TrulancePlecanatide11$5,647
Gabapentin323$5,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,188$93,70880 claims
Lilly USA, LLCTrulicity, Mounjaro$1,218$59,32056 claims
PfizerEliquis$1,865$52,68751 claims
Boehringer IngelheimJardiance$258$40,87836 claims
AstraZenecaFarxiga, Symbicort$1,204$31,89738 claims
Johnson & JohnsonXarelto$688$16,73220 claims
GSKTrelegy Ellipta$1,305$15,39418 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$509$14,32216 claims
Astellas Pharma US IncMyrbetriq$185$12,85714 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$551$5,64711 claims
AbbVieSynthroid$1,400$3,27035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →